CRISPR Therapeutics
CRSP
253 hedge funds and large institutions have $1.92B invested in CRISPR Therapeutics in 2019 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 68 increasing their positions, 52 reducing their positions, and 18 closing their positions.
406% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 18
70% more capital invested
Capital invested by funds: $1.13B → $1.92B (+$791M)
39% more funds holding
Funds holding: 182 → 253 (+71)
31% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 52
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
2.91% more ownership
Funds ownership: 50.39% → 53.3% (+2.9%)
4% less call options, than puts
Call options by funds: $55.6M | Put options by funds: $58.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$24.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$21.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.7M |
| 5 |
Two Sigma Investments
New York
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.3M |
| 2 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$13.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$11.5M |
| 4 |
AC
Armistice Capital
New York
|
-$6.33M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$6.2M |
CRSP Hedge Fund Activity: Q4 2019 in Review
253 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2019, worth a combined $1.92B — up 70% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new CRSP positions and 18 closed out — a net gain of 73 holders — while 68 added to existing stakes and 52 trimmed.
The largest buyer was Ameriprise, adding an estimated $24.5M. The largest seller was Wellington Management Group, cutting an estimated $15.3M.
- 253 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2019, up from 182 in Q3 2019.
- Funds reported $1.92B of CRISPR Therapeutics stock for Q4 2019, up 70% quarter-over-quarter.
- 91 funds opened new CRISPR Therapeutics positions in Q4 2019 and 18 closed out, a net change of +73 holders.
- The largest CRISPR Therapeutics buyer in Q4 2019 was Ameriprise, an estimated $24.5M added.
- The largest CRISPR Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $15.3M sold.
Based on aggregated 13F filings for Q4 2019.